{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:25Z","timestamp":1792788565908,"version":"4.5.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100018713","name":"Center for Innovative Medicine","doi-asserted-by":"publisher","award":["FoUI-963234"],"award-info":[{"award-number":["FoUI-963234"]}],"id":[{"id":"10.13039\/501100018713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220271"],"award-info":[{"award-number":["20220271"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ALF Medicin by Region Stockholm","award":["FOUI-962738"],"award-info":[{"award-number":["FOUI-962738"]}],"id":[{"id":"https:\/\/ror.org\/02zrae794","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc. Diabetol. \u2013 Endocrinol. Rep."],"DOI":"10.1186\/s40842-026-00336-x","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:14:12Z","timestamp":1791238452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiometabolic diseases in transgender populations"],"prefix":"10.1186","volume":"12","author":[{"given":"Mattia","family":"Fienga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe J. F.","family":"Tietge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"336_CR1","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jsxm.2018.01.016","volume":"15","author":"CM Wiepjes","year":"2018","unstructured":"Wiepjes CM, Nota NM, De Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972\u20132015): Trends in Prevalence, Treatment, and Regrets. J Sex Med. 2018;15:582\u201390. https:\/\/doi.org\/10.1016\/j.jsxm.2018.01.016.","journal-title":"J Sex Med"},{"key":"336_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/archdischild-2024-327992","volume":"110","author":"SW Jarvis","year":"2025","unstructured":"Jarvis SW, Fraser LK, Langton T, et al. Epidemiology of gender dysphoria and gender incongruence in children and young people attending primary care practices in England: retrospective cohort study. Arch Dis Child. 2025;110:612\u201321. https:\/\/doi.org\/10.1136\/archdischild-2024-327992.","journal-title":"Arch Dis Child"},{"key":"336_CR3","doi-asserted-by":"publisher","first-page":"e100972","DOI":"10.1136\/gpsych-2022-100972","volume":"36","author":"C-F Sun","year":"2023","unstructured":"Sun C-F, Xie H, Metsutnan V, et al. The mean age of gender dysphoria diagnosis is decreasing. Gen Psychiatry. 2023;36:e100972. https:\/\/doi.org\/10.1136\/gpsych-2022-100972.","journal-title":"Gen Psychiatry"},{"key":"336_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/joim.13441","volume":"291","author":"L D\u2019hoore","year":"2022","unstructured":"D\u2019hoore L, T\u2019Sjoen G. Gender-affirming hormone therapy: An updated literature review with an eye on the future. J Intern Med. 2022;291:574\u201392. https:\/\/doi.org\/10.1111\/joim.13441.","journal-title":"J Intern Med"},{"key":"336_CR5","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1093\/ejendo\/lvad170","volume":"190","author":"LM van Zijverden","year":"2024","unstructured":"van Zijverden LM, Wiepjes CM, van Diemen JJK, et al. Cardiovascular disease in transgender people: a systematic review and meta-analysis. Eur J Endocrinol. 2024;190:S13\u201324. https:\/\/doi.org\/10.1093\/ejendo\/lvad170.","journal-title":"Eur J Endocrinol"},{"key":"336_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.thromres.2024.02.029","volume":"236","author":"D Tienforti","year":"2024","unstructured":"Tienforti D, Pastori D, Barbonetti A. Effects of gender affirming hormone therapy with testosterone on coagulation and hematological parameters in transgender people assigned female at birth: A systematic review and meta-analysis. Thromb Res. 2024;236:170\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2024.02.029.","journal-title":"Thromb Res"},{"key":"336_CR7","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148:1606\u201335. https:\/\/doi.org\/10.1161\/CIR.0000000000001184.","journal-title":"Circulation"},{"key":"336_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-025-00740-5","author":"C Kaldirimitzian","year":"2025","unstructured":"Kaldirimitzian C, Kampanella L, Chouliara K-M, et al. New insights into sexual dimorphism in cardiometabolic health. Hormones. 2025. https:\/\/doi.org\/10.1007\/s42000-025-00740-5.","journal-title":"Hormones"},{"key":"336_CR9","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1210\/clinem\/dgae226","volume":"109","author":"R Shepherd","year":"2024","unstructured":"Shepherd R, Angus LM, Mansell T, et al. Impact of Distinct Antiandrogen Exposures on the Plasma Metabolome in Feminizing Gender-affirming Hormone Therapy. J Clin Endocrinol Metab. 2024;109:2857\u201371. https:\/\/doi.org\/10.1210\/clinem\/dgae226.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR10","doi-asserted-by":"publisher","first-page":"2567294","DOI":"10.1080\/09537104.2025.2567294","volume":"36","author":"LM van Zijverden","year":"2025","unstructured":"van Zijverden LM, Schutte MH, Tebbens M, et al. The effect of testosterone on platelet activation and inflammation in transgender men. Platelets. 2025;36:2567294. https:\/\/doi.org\/10.1080\/09537104.2025.2567294.","journal-title":"Platelets"},{"key":"336_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.668252","author":"DF Deegan","year":"2021","unstructured":"Deegan DF, Nigam P, Engel N. Sexual Dimorphism of the Heart: Genetics, Epigenetics, and Development. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.668252. 8:.","journal-title":"Front Cardiovasc Med"},{"key":"336_CR12","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/s41366-023-01339-9","volume":"47","author":"JL Carter","year":"2023","unstructured":"Carter JL, Abdullah N, Bragg F, et al. Body composition and risk factors for cardiovascular disease in global multi-ethnic populations. Int J Obes. 2023;47:855\u201364. https:\/\/doi.org\/10.1038\/s41366-023-01339-9.","journal-title":"Int J Obes"},{"key":"336_CR13","doi-asserted-by":"publisher","first-page":"109423","DOI":"10.1016\/j.steroids.2024.109423","volume":"206","author":"A Cignarella","year":"2024","unstructured":"Cignarella A, Bolego C, Barton M. Sex and sex steroids as determinants of cardiovascular risk. Steroids. 2024;206:109423. https:\/\/doi.org\/10.1016\/j.steroids.2024.109423.","journal-title":"Steroids"},{"key":"336_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.focus.2023.100096","author":"TC Poteat","year":"2023","unstructured":"Poteat TC, Rich AJ, Jiang H, et al. AJPM Focus. 2023;2:100096. https:\/\/doi.org\/10.1016\/j.focus.2023.100096. Cardiovascular Disease Risk Estimation for Transgender and Gender-Diverse Patients: Cross-Sectional Analysis of Baseline Data From the LITE Plus Cohort Study."},{"key":"336_CR15","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1111\/imj.70194","volume":"55","author":"K Saxby","year":"2025","unstructured":"Saxby K, Nolan BJ. Temporal trends in gender-affirming hormone therapy initiation: evidence from whole\u2010of\u2010population Australian administrative data. Intern Med J. 2025;55:2092\u20134. https:\/\/doi.org\/10.1111\/imj.70194.","journal-title":"Intern Med J"},{"key":"336_CR16","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296\u2013305. https:\/\/doi.org\/10.1056\/NEJMoa041031.","journal-title":"N Engl J Med"},{"key":"336_CR17","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2215\/CJN.0000000000000289","volume":"18","author":"SA van Eeghen","year":"2023","unstructured":"van Eeghen SA, Wiepjes CM, T\u2019Sjoen G, et al. Cystatin C\u2013Based eGFR Changes during Gender-Affirming Hormone Therapy in Transgender Individuals. Clin J Am Soc Nephrol CJASN. 2023;18:1545\u201354. https:\/\/doi.org\/10.2215\/CJN.0000000000000289.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"336_CR18","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1007\/s00125-025-06572-7","volume":"68","author":"MS Duncan","year":"2025","unstructured":"Duncan MS, Beach LB, Wolfe HL, et al. Sexual orientation, gender identity and cardiometabolic risk: a narrative review. Diabetologia. 2025;68:2652\u201369. https:\/\/doi.org\/10.1007\/s00125-025-06572-7.","journal-title":"Diabetologia"},{"key":"336_CR19","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1161\/CIR.0000000000001003","volume":"144","author":"CG Streed","year":"2021","unstructured":"Streed CG, Beach LB, Caceres BA, et al. Assessing and Addressing Cardiovascular Health in People Who Are Transgender and Gender Diverse: A Scientific Statement From the American Heart Association. Circulation. 2021;144:e136\u201348. https:\/\/doi.org\/10.1161\/CIR.0000000000001003.","journal-title":"Circulation"},{"key":"336_CR20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1210\/clinem\/dgab089","volume":"106","author":"MC Madsen","year":"2021","unstructured":"Madsen MC, van Dijk D, Wiepjes CM, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. J Clin Endocrinol Metab. 2021;106:1710\u20137. https:\/\/doi.org\/10.1210\/clinem\/dgab089.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR21","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","volume":"366","author":"\u00d8 Lidegaard","year":"2012","unstructured":"Lidegaard \u00d8, L\u00f8kkegaard E, Jensen A, et al. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1111840.","journal-title":"N Engl J Med"},{"key":"336_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/nau.25097","volume":"42","author":"D Sudhakar","year":"2023","unstructured":"Sudhakar D, Huang Z, Zietkowski M, et al. Feminizing gender-affirming hormone therapy for the transgender and gender diverse population: An overview of treatment modality, monitoring, and risks. Neurourol Urodyn. 2023;42:903\u201320. https:\/\/doi.org\/10.1002\/nau.25097.","journal-title":"Neurourol Urodyn"},{"key":"336_CR23","doi-asserted-by":"publisher","first-page":"87784","DOI":"10.21037\/tau.2016.09.04","volume":"5","author":"CA Unger","year":"2016","unstructured":"Unger CA. Hormone therapy for transgender patients. Transl Androl Urol. 2016;5:87784\u2013884. https:\/\/doi.org\/10.21037\/tau.2016.09.04.","journal-title":"Transl Androl Urol"},{"key":"336_CR24","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1089\/lgbt.2020.0026","volume":"7","author":"L Perl","year":"2020","unstructured":"Perl L, Segev-Becker A, Israeli G, et al. Blood Pressure Dynamics After Pubertal Suppression with Gonadotropin-Releasing Hormone Analogs Followed by Testosterone Treatment in Transgender Male Adolescents: A Pilot Study. LGBT Health. 2020;7:340\u20134. https:\/\/doi.org\/10.1089\/lgbt.2020.0026.","journal-title":"LGBT Health"},{"key":"336_CR25","doi-asserted-by":"publisher","unstructured":"Diana P, Adu-Gyamfi K, Butler G. Effect of puberty suppression and gender affirming hormone treatment depends upon prior extent of pubertal development in young transgender adolescents. Horm Res Paediatr. 2025;1\u201319. https:\/\/doi.org\/10.1159\/000548004.","DOI":"10.1159\/000548004"},{"key":"336_CR26","doi-asserted-by":"publisher","first-page":"204201882098568","DOI":"10.1177\/2042018820985681","volume":"12","author":"I Bretherton","year":"2021","unstructured":"Bretherton I, Spanos C, Leemaqz SY, et al. Insulin resistance in transgender individuals correlates with android fat mass. Ther Adv Endocrinol Metab. 2021;12:2042018820985681. https:\/\/doi.org\/10.1177\/2042018820985681.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"336_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jsxm.2021.01.185","volume":"18","author":"C Cocchetti","year":"2021","unstructured":"Cocchetti C, Castellini G, Iacuaniello D, et al. Does Gender-Affirming Hormonal Treatment Affect 30-Year Cardiovascular Risk in Transgender Persons? A Two-Year Prospective European Study (ENIGI). J Sex Med. 2021;18:821\u20139. https:\/\/doi.org\/10.1016\/j.jsxm.2021.01.185.","journal-title":"J Sex Med"},{"key":"336_CR28","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1097\/AOG.0000000000000692","volume":"125","author":"MB Deutsch","year":"2015","unstructured":"Deutsch MB, Bhakri V, Kubicek K. Effects of Cross-Sex Hormone Treatment on Transgender Women and Men. Obstet Gynecol. 2015;125:605\u201310. https:\/\/doi.org\/10.1097\/AOG.0000000000000692.","journal-title":"Obstet Gynecol"},{"key":"336_CR29","doi-asserted-by":"publisher","first-page":"e2419696","DOI":"10.1001\/jamanetworkopen.2024.19696","volume":"7","author":"L Hashemi","year":"2024","unstructured":"Hashemi L, Marijic Buljubasic A, Budoff MJ, et al. Gender-Affirming Hormone Treatment and Metabolic Syndrome Among Transgender Veterans. JAMA Netw Open. 2024;7:e2419696. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.19696.","journal-title":"JAMA Netw Open"},{"key":"336_CR30","doi-asserted-by":"publisher","first-page":"e2273","DOI":"10.1210\/clinem\/dgae745","volume":"110","author":"Y Lei","year":"2025","unstructured":"Lei Y, Wiik A, Connelly MA, et al. Cardiometabolic Risk Assessment in Transgender Individuals\u2014Differential Effect of Sex Hormones and Sex Chromosomes. J Clin Endocrinol Metab. 2025;110:e2273\u201384. https:\/\/doi.org\/10.1210\/clinem\/dgae745.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/JCMA.0000000000000475","volume":"84","author":"Y-H Liu","year":"2021","unstructured":"Liu Y-H, Wu T-H, Chu C-H, et al. Metabolic effects of cross-sex hormone therapy in transgender individuals in Taiwan. J Chin Med Assoc JCMA. 2021;84:267\u201372. https:\/\/doi.org\/10.1097\/JCMA.0000000000000475.","journal-title":"J Chin Med Assoc JCMA"},{"key":"336_CR32","doi-asserted-by":"publisher","first-page":"100379","DOI":"10.1016\/j.jcte.2024.100379","volume":"39","author":"D Slukov\u00e1","year":"2024","unstructured":"Slukov\u00e1 D, Deischinger C, Just I, et al. The effects of gender-affirming hormone therapy on myocardial, hepatic, pancreatic lipid content, body fat distribution and other cardiometabolic risk factors: A magnetic resonance-based study in transgender individuals. J Clin Transl Endocrinol. 2024;39:100379. https:\/\/doi.org\/10.1016\/j.jcte.2024.100379.","journal-title":"J Clin Transl Endocrinol"},{"key":"336_CR33","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1089\/trgh.2024.0012","volume":"10","author":"N Vehmas","year":"2025","unstructured":"Vehmas N, Holopainen E, Savolainen-Peltonen H. Metabolic and Anthropometric Changes and Adverse Effects in Finnish Adolescents Using Gender-Affirming Hormonal Treatment. Transgender Health. 2025;10:306\u201315. https:\/\/doi.org\/10.1089\/trgh.2024.0012.","journal-title":"Transgender Health"},{"key":"336_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.maturitas.2017.10.012","volume":"107","author":"R Vita","year":"2018","unstructured":"Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: A cohort study. Maturitas. 2018;107:92\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2017.10.012.","journal-title":"Maturitas"},{"key":"336_CR35","doi-asserted-by":"publisher","first-page":"100230","DOI":"10.1016\/j.jcte.2020.100230","volume":"21","author":"P Suppakitjanusant","year":"2020","unstructured":"Suppakitjanusant P, Ji Y, Stevenson MO, et al. Effects of gender affirming hormone therapy on body mass index in transgender individuals: A longitudinal cohort study. J Clin Transl Endocrinol. 2020;21:100230. https:\/\/doi.org\/10.1016\/j.jcte.2020.100230.","journal-title":"J Clin Transl Endocrinol"},{"key":"336_CR36","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/jcm12196141","volume":"12","author":"E S\u00e1nchez-Toscano","year":"2023","unstructured":"S\u00e1nchez-Toscano E, Dom\u00ednguez-Riscart J, Larr\u00e1n-Escand\u00f3n L, et al. Cardiovascular Risk Factors in Transgender People after Gender-Affirming Hormone Therapy. J Clin Med. 2023;12:6141. https:\/\/doi.org\/10.3390\/jcm12196141.","journal-title":"J Clin Med"},{"key":"336_CR37","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1210\/clinem\/dgab616","volume":"107","author":"M Klaver","year":"2021","unstructured":"Klaver M, van Velzen D, de Blok C, et al. Change in Visceral Fat and Total Body Fat and the Effect on Cardiometabolic Risk Factors During Transgender Hormone Therapy. J Clin Endocrinol Metab. 2021;107:e153\u201364. https:\/\/doi.org\/10.1210\/clinem\/dgab616.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR38","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/joim.20039","volume":"297","author":"TR Lundberg","year":"2025","unstructured":"Lundberg TR, Tryfonos A, Eriksson LMJ, et al. Longitudinal changes in regional fat and muscle composition and cardiometabolic biomarkers over 5 years of hormone therapy in transgender individuals. J Intern Med. 2025;297:156\u201372. https:\/\/doi.org\/10.1111\/joim.20039.","journal-title":"J Intern Med"},{"key":"336_CR39","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/cen.13607","volume":"88","author":"TM Fighera","year":"2018","unstructured":"Fighera TM, da Silva E, Lindenau JD-R, Spritzer PM. Impact of cross-sex hormone therapy on bone mineral density and body composition in transwomen. Clin Endocrinol (Oxf). 2018;88:856\u201362. https:\/\/doi.org\/10.1111\/cen.13607.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"336_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1089\/trgh.2016.0016","volume":"1","author":"MD Nelson","year":"2016","unstructured":"Nelson MD, Szczepaniak LS, Wei J, et al. Transwomen and the Metabolic Syndrome: Is Orchiectomy. Protective? Transgender Health. 2016;1:165\u201371. https:\/\/doi.org\/10.1089\/trgh.2016.0016.","journal-title":"Protective? Transgender Health"},{"key":"336_CR41","doi-asserted-by":"publisher","first-page":"6001","DOI":"10.3390\/jcm13196001","volume":"13","author":"R Hamid","year":"2024","unstructured":"Hamid R, G\u00fcll\u00fcce A, Karg\u0131n OA, et al. Assessing the Influence of Long-Term Gender-Affirming Hormone Therapy on Cardiovascular Risk in Transgender Men through Carotid Intima\u2013Media Thickness. J Clin Med. 2024;13:6001. https:\/\/doi.org\/10.3390\/jcm13196001.","journal-title":"J Clin Med"},{"key":"336_CR42","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/JRS-200087","volume":"34","author":"C Milionis","year":"2023","unstructured":"Milionis C, Ilias I, Venaki E, Koukkou E. The metabolic effects of hormonal treatment in transgender males: Safety of the testosterone gender-affirming therapy. Int J Risk Saf Med. 2023;34:21\u20138. https:\/\/doi.org\/10.3233\/JRS-200087.","journal-title":"Int J Risk Saf Med"},{"key":"336_CR43","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1111\/andr.13832","volume":"13","author":"LF Buhl","year":"2025","unstructured":"Buhl LF, Andersen MS, Frystyk J, et al. Cardiac function and coronary plaque development following masculinizing gender-affirming hormone therapy: A prospective cohort study. Andrology. 2025;13:2195\u2013205. https:\/\/doi.org\/10.1111\/andr.13832.","journal-title":"Andrology"},{"key":"336_CR44","doi-asserted-by":"publisher","first-page":"205031212110515","DOI":"10.1177\/20503121211051546","volume":"9","author":"S Korpaisarn","year":"2021","unstructured":"Korpaisarn S, Chiewchalermsri D, Arunakul J, et al. Effects of testosterone treatment on transgender males: A single-institution study. SAGE Open Med. 2021;9:20503121211051546. https:\/\/doi.org\/10.1177\/20503121211051546.","journal-title":"SAGE Open Med"},{"key":"336_CR45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.fertnstert.2020.08.002","volume":"115","author":"F Iannantuoni","year":"2021","unstructured":"Iannantuoni F, Salazar JD, Martinez de Mara\u00f1on A, et al. Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men. Fertil Steril. 2021;115:483\u20139. https:\/\/doi.org\/10.1016\/j.fertnstert.2020.08.002.","journal-title":"Fertil Steril"},{"key":"336_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/biomedicines11030670","volume":"11","author":"C Milionis","year":"2023","unstructured":"Milionis C, Ilias I, Venaki E, Koukkou E. Glucose Homeostasis, Diabetes Mellitus, and Gender-Affirming Treatment. Biomedicines. 2023;11:670. https:\/\/doi.org\/10.3390\/biomedicines11030670.","journal-title":"Biomedicines"},{"key":"336_CR47","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412\u20139. https:\/\/doi.org\/10.1007\/BF00280883.","journal-title":"Diabetologia"},{"key":"336_CR48","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1210\/clinem\/dgae353","volume":"110","author":"O Anike","year":"2024","unstructured":"Anike O, Zhang Q, Bhasin S, et al. Association Between Gender-affirming Hormone Therapy and Measures of Glucose Metabolism: A Longitudinal Study. J Clin Endocrinol Metab. 2024;110:289\u201396. https:\/\/doi.org\/10.1210\/clinem\/dgae353.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR49","doi-asserted-by":"publisher","first-page":"e704","DOI":"10.1210\/clinem\/dgz029","volume":"105","author":"NJ Nokoff","year":"2019","unstructured":"Nokoff NJ, Scarbro SL, Moreau KL, et al. Body Composition and Markers of Cardiometabolic Health in Transgender Youth Compared With Cisgender Youth. J Clin Endocrinol Metab. 2019;105:e704\u201314. https:\/\/doi.org\/10.1210\/clinem\/dgz029.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR50","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1111\/hiv.13522","volume":"24","author":"JE Lake","year":"2023","unstructured":"Lake JE, Miao H, Bowman ER, et al. GENDER-AFFIRMING HORMONE THERAPY DECREASES D-DIMER BUT WORSENS INSULIN SENSITIVITY IN TRANSGENDER WOMEN. HIV Med. 2023;24:1144\u20139. https:\/\/doi.org\/10.1111\/hiv.13522.","journal-title":"HIV Med"},{"key":"336_CR51","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/lgbt.2023.0010","volume":"10","author":"CA Martinez","year":"2023","unstructured":"Martinez CA, Rikhi R, Fonseca Nogueira N, et al. Estrogen-Based Gender-Affirming Hormone Therapy and Subclinical Cardiovascular Disease in Transgender Women with HIV. LGBT Health. 2023;10:576\u201385. https:\/\/doi.org\/10.1089\/lgbt.2023.0010.","journal-title":"LGBT Health"},{"key":"336_CR52","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jsxm.2017.03.251","volume":"14","author":"LJW Tack","year":"2017","unstructured":"Tack LJW, Heyse R, Craen M, et al. Consecutive Cyproterone Acetate and Estradiol Treatment in Late-Pubertal Transgender Female Adolescents. J Sex Med. 2017;14:747\u201357. https:\/\/doi.org\/10.1016\/j.jsxm.2017.03.251.","journal-title":"J Sex Med"},{"key":"336_CR53","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.13821","volume":"89","author":"G Gava","year":"2018","unstructured":"Gava G, Mancini I, Cerpolini S, et al. Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. Clin Endocrinol (Oxf). 2018;89:878\u201386. https:\/\/doi.org\/10.1111\/cen.13821.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"336_CR54","doi-asserted-by":"publisher","first-page":"100356","DOI":"10.1016\/j.jcte.2024.100356","volume":"36","author":"NJ Nokoff","year":"2024","unstructured":"Nokoff NJ, Bothwell S, Rice JD, et al. Insulin sensitivity, body composition and bone mineral density after testosterone treatment in transgender youth with and without prior GnRH agonist therapy. J Clin Transl Endocrinol. 2024;36:100356. https:\/\/doi.org\/10.1016\/j.jcte.2024.100356.","journal-title":"J Clin Transl Endocrinol"},{"key":"336_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2265.2009.03632.x","volume":"72","author":"MB Elamin","year":"2010","unstructured":"Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol (Oxf). 2010;72:1\u201310. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03632.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"336_CR56","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1210\/jc.2018-02138","volume":"104","author":"DM van Velzen","year":"2019","unstructured":"van Velzen DM, Paldino A, Klaver M, et al. Cardiometabolic Effects of Testosterone in Transmen and Estrogen Plus Cyproterone Acetate in Transwomen. J Clin Endocrinol Metab. 2019;104:1937\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02138.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR57","doi-asserted-by":"publisher","first-page":"667403","DOI":"10.3389\/fendo.2021.667403","volume":"12","author":"MI Balcerek","year":"2021","unstructured":"Balcerek MI, Nolan BJ, Brownhill A, et al. Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia. Front Endocrinol. 2021;12:667403. https:\/\/doi.org\/10.3389\/fendo.2021.667403.","journal-title":"Front Endocrinol"},{"key":"336_CR58","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jacl.2021.09.051","volume":"15","author":"K Millington","year":"2021","unstructured":"Millington K, Chan Y-M. Lipoprotein subtypes after testosterone therapy in transmasculine adolescents. J Clin Lipidol. 2021;15:840\u20134. https:\/\/doi.org\/10.1016\/j.jacl.2021.09.051.","journal-title":"J Clin Lipidol"},{"key":"336_CR59","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.03.008","volume":"323","author":"DM van Velzen","year":"2021","unstructured":"van Velzen DM, Adorni MP, Zimetti F, et al. The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis. 2021;323:44\u201353. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.03.008.","journal-title":"Atherosclerosis"},{"key":"336_CR60","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK, HIGH BLOOD PRESSURE AND CARDIOVASCULAR DISEASE. Hypertens Dallas Tex 1979. 2020;75:285\u201392. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14240.","journal-title":"Hypertens Dallas Tex 1979"},{"key":"336_CR61","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1089\/trgh.2022.0062","volume":"9","author":"ACG Ferreira","year":"2024","unstructured":"Ferreira ACG, Moreira RC, Coelho LE, et al. Association of Current and Long-Term Estradiol Use with Carotid Intima Media Thickness Among Transgender Women: A Cross-Sectional Study. Transgender Health. 2024;9:492\u2013500. https:\/\/doi.org\/10.1089\/trgh.2022.0062.","journal-title":"Transgender Health"},{"key":"336_CR62","doi-asserted-by":"publisher","first-page":"bvae120","DOI":"10.1210\/jendso\/bvae120","volume":"8","author":"JE Lake","year":"2024","unstructured":"Lake JE, Feng H, Hyatt AN, et al. Transgender Women With Suppressed Testosterone Display Lower Burden of Coronary Disease Than Matched Cisgender Men. J Endocr Soc. 2024;8:bvae120. https:\/\/doi.org\/10.1210\/jendso\/bvae120.","journal-title":"J Endocr Soc"},{"key":"336_CR63","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.jsxm.2019.06.014","volume":"16","author":"IE Stoffers","year":"2019","unstructured":"Stoffers IE, de Vries MC, Hannema SE. Physical Changes, Laboratory Parameters, and Bone Mineral Density During Testosterone Treatment in Adolescents with Gender Dysphoria. J Sex Med. 2019;16:1459\u201368. https:\/\/doi.org\/10.1016\/j.jsxm.2019.06.014.","journal-title":"J Sex Med"},{"key":"336_CR64","doi-asserted-by":"publisher","first-page":"bvad040","DOI":"10.1210\/jendso\/bvad040","volume":"7","author":"FS Cunha","year":"2023","unstructured":"Cunha FS, Bachega TASS, Costa EMF, et al. Arterial Stiffness in Transgender Men Receiving Long-term Testosterone Therapy. J Endocr Soc. 2023;7:bvad040. https:\/\/doi.org\/10.1210\/jendso\/bvad040.","journal-title":"J Endocr Soc"},{"key":"336_CR65","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s11154-018-9454-3","volume":"19","author":"MS Irwig","year":"2018","unstructured":"Irwig MS. Cardiovascular health in transgender people. Rev Endocr Metab Disord. 2018;19:243\u201351. https:\/\/doi.org\/10.1007\/s11154-018-9454-3.","journal-title":"Rev Endocr Metab Disord"},{"key":"336_CR66","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1089\/trgh.2022.0182","volume":"9","author":"JE Lake","year":"2024","unstructured":"Lake JE, Hyatt AN, Feng H, et al. Transgender Women with HIV Demonstrate Unique Non-Alcoholic Fatty Liver Disease Profiles. Transgender Health. 2024;9:413\u201320. https:\/\/doi.org\/10.1089\/trgh.2022.0182.","journal-title":"Transgender Health"},{"key":"336_CR67","doi-asserted-by":"publisher","first-page":"e0261312","DOI":"10.1371\/journal.pone.0261312","volume":"17","author":"MH Schutte","year":"2022","unstructured":"Schutte MH, Kleemann R, Nota NM, et al. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. PLoS ONE. 2022;17:e0261312. https:\/\/doi.org\/10.1371\/journal.pone.0261312.","journal-title":"PLoS ONE"},{"key":"336_CR68","doi-asserted-by":"publisher","first-page":"e0323606","DOI":"10.1371\/journal.pone.0323606","volume":"20","author":"PD da Cruz","year":"2025","unstructured":"da Cruz PD, Santos BR, Spritzer PM. Hemostatic parameters in transgender women receiving gender-affirming hormone therapy: A shift to a cisgender female pattern? PLoS ONE. 2025;20:e0323606. https:\/\/doi.org\/10.1371\/journal.pone.0323606.","journal-title":"PLoS ONE"},{"key":"336_CR69","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1210\/jcem.82.10.4284","volume":"82","author":"JM Elbers","year":"1997","unstructured":"Elbers JM, Asscheman H, Seidell JC, et al. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab. 1997;82:3267\u201370. https:\/\/doi.org\/10.1210\/jcem.82.10.4284.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR70","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1524-6175.2006.05156.x","volume":"8","author":"A Whaley-Connell","year":"2007","unstructured":"Whaley-Connell A, Sowers JR. Chronic Kidney Disease and the Cardiometabolic Syndrome. J Clin Hypertens. 2007;8:546\u20138. https:\/\/doi.org\/10.1111\/j.1524-6175.2006.05156.x.","journal-title":"J Clin Hypertens"},{"key":"336_CR71","volume-title":"Chronic Kidney Disease","author":"SR Vaidya","year":"2025","unstructured":"Vaidya SR, Aeddula NR. Chronic Kidney Disease. Treasure Island (FL): In: StatPearls. StatPearls Publishing; 2025."},{"key":"336_CR72","doi-asserted-by":"publisher","first-page":"99","DOI":"10.12860\/jnp.2014.19","volume":"3","author":"S Said","year":"2014","unstructured":"Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol. 2014;3:99\u2013104. https:\/\/doi.org\/10.12860\/jnp.2014.19.","journal-title":"J Nephropathol"},{"key":"336_CR73","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/jalm\/jfac025F","volume":"7","author":"RM Humble","year":"2022","unstructured":"Humble RM, Greene DN, Schmidt RL, et al. Reference Intervals for Clinical Chemistry Analytes for Transgender Men and Women on Stable Hormone Therapy. J Appl Lab Med. 2022;7:1131\u201344. https:\/\/doi.org\/10.1093\/jalm\/jfac025F.","journal-title":"J Appl Lab Med"},{"key":"336_CR74","doi-asserted-by":"publisher","first-page":"101051","DOI":"10.1016\/j.xkme.2025.101051","volume":"7","author":"SJ Leon","year":"2025","unstructured":"Leon SJ, Ferguson TW, Whitlock R, et al. Gender-affirming Hormone Therapy and Changes in Kidney Function in Adults: A Retrospective Population-based Study. Kidney Med. 2025;7:101051. https:\/\/doi.org\/10.1016\/j.xkme.2025.101051.","journal-title":"Kidney Med"},{"key":"336_CR75","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","volume":"78","author":"LA Inker","year":"2021","unstructured":"Inker LA, Titan S. Measurement and Estimation of GFR for Use in Clinical Practice: Core Curriculum 2021. Am J Kidney Dis. 2021;78:736\u201349. https:\/\/doi.org\/10.1053\/j.ajkd.2021.04.016.","journal-title":"Am J Kidney Dis"},{"key":"336_CR76","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s00392-020-01709-7","volume":"110","author":"P Kasper","year":"2021","unstructured":"Kasper P, Martin A, Lang S, et al. NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2021;110:921\u201337. https:\/\/doi.org\/10.1007\/s00392-020-01709-7.","journal-title":"Clin Res Cardiol"},{"key":"336_CR77","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.jsxm.2021.06.011","volume":"18","author":"L Hashemi","year":"2021","unstructured":"Hashemi L, Zhang Q, Getahun D, et al. Longitudinal Changes in Liver Enzyme Levels Among Transgender People Receiving Gender Affirming Hormone Therapy. J Sex Med. 2021;18:1662\u201375. https:\/\/doi.org\/10.1016\/j.jsxm.2021.06.011.","journal-title":"J Sex Med"},{"key":"336_CR78","doi-asserted-by":"publisher","first-page":"e4004","DOI":"10.1210\/clinem\/dgac469","volume":"107","author":"A Valentine","year":"2022","unstructured":"Valentine A, Davis S, Furniss A, et al. Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study. J Clin Endocrinol Metab. 2022;107:e4004\u201314. https:\/\/doi.org\/10.1210\/clinem\/dgac469.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR79","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7326\/M17-2785","volume":"169","author":"D Getahun","year":"2018","unstructured":"Getahun D, Nash R, Flanders WD, et al. Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons. Ann Intern Med. 2018;169:205\u201313. https:\/\/doi.org\/10.7326\/M17-2785.","journal-title":"Ann Intern Med"},{"key":"336_CR80","doi-asserted-by":"publisher","unstructured":"van Zijverden LM, Thijs A, van Diemen JJK, et al. Transgender persons receiving gender-affirming hormone therapy: risk of acute cardiovascular events in a Dutch cohort study. Eur Heart J ehaf. 2025;837. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf837.","DOI":"10.1093\/eurheartj\/ehaf837"},{"key":"336_CR81","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/eurjpc\/zwac133","volume":"29","author":"MA Karalexi","year":"2022","unstructured":"Karalexi MA, Frisell T, Cnattingius S, et al. Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. Eur J Prev Cardiol. 2022;29:2017\u201326. https:\/\/doi.org\/10.1093\/eurjpc\/zwac133.","journal-title":"Eur J Prev Cardiol"},{"key":"336_CR82","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","volume":"139","author":"NM Nota","year":"2019","unstructured":"Nota NM, Wiepjes CM, de Blok CJM, et al. Occurrence of Acute Cardiovascular Events in Transgender Individuals Receiving Hormone Therapy. Circulation. 2019;139:1461\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038584.","journal-title":"Circulation"},{"key":"336_CR83","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.amepre.2021.05.019","volume":"61","author":"T Poteat","year":"2021","unstructured":"Poteat T, Divsalar S, Streed C, et al. Cardiovascular disease in a population-based sample of transgender and cisgender adults. Am J Prev Med. 2021;61:804\u201311. https:\/\/doi.org\/10.1016\/j.amepre.2021.05.019.","journal-title":"Am J Prev Med"},{"key":"336_CR84","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1530\/EJE-13-0493","volume":"169","author":"K Wierckx","year":"2013","unstructured":"Wierckx K, Elaut E, Declercq E, et al. Prevalence of cardiovascular disease and cancer during cross-sex hormone therapy in a large cohort of trans persons: a case\u2013control study. Eur J Endocrinol. 2013;169:471\u20138. https:\/\/doi.org\/10.1530\/EJE-13-0493.","journal-title":"Eur J Endocrinol"},{"key":"336_CR85","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","volume":"9","author":"CJ de Blok","year":"2021","unstructured":"de Blok CJ, Wiepjes CM, van Velzen DM, et al. Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. Lancet Diabetes Endocrinol. 2021;9:663\u201370. https:\/\/doi.org\/10.1016\/S2213-8587(21)00185-6.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"336_CR86","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/ejendo\/lvaf183","volume":"193","author":"F Bonnet","year":"2025","unstructured":"Bonnet F, Vaduva P, Balkau B, et al. Testosterone therapy and the risk of atrial fibrillation, venous thromboembolism and cardiovascular events in cis men with hypogonadism and trans men. Eur J Endocrinol. 2025;193:374\u201382. https:\/\/doi.org\/10.1093\/ejendo\/lvaf183.","journal-title":"Eur J Endocrinol"},{"key":"336_CR87","doi-asserted-by":"publisher","first-page":"e1515","DOI":"10.1210\/clinem\/dgad388","volume":"108","author":"DS Lopez","year":"2023","unstructured":"Lopez DS, Mulla JS, El Haddad D, et al. Testosterone Replacement Therapy in Relation With Cardiovascular Disease in Cisgender Women and Transgender People. J Clin Endocrinol Metab. 2023;108:e1515\u201323. https:\/\/doi.org\/10.1210\/clinem\/dgad388.","journal-title":"J Clin Endocrinol Metab"},{"key":"336_CR88","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s11606-025-09701-5","volume":"40","author":"CG Streed","year":"2025","unstructured":"Streed CG, Duncan MS, Heier KR, et al. Incident Atherosclerotic Cardiovascular Disease Among Veterans by Gender Identity: A Cohort Study. J Gen Intern Med. 2025;40:3149\u201358. https:\/\/doi.org\/10.1007\/s11606-025-09701-5.","journal-title":"J Gen Intern Med"},{"key":"336_CR89","doi-asserted-by":"publisher","first-page":"e2020023549","DOI":"10.1542\/peds.2020-023549","volume":"147","author":"ES Mullins","year":"2021","unstructured":"Mullins ES, Geer R, Metcalf M, et al. Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy. Pediatrics. 2021;147:e2020023549. https:\/\/doi.org\/10.1542\/peds.2020-023549.","journal-title":"Pediatrics"},{"key":"336_CR90","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s44324-024-00036-z","volume":"2","author":"AK Ziegler","year":"2024","unstructured":"Ziegler AK, Scheele C. Human adipose depots\u2019 diverse functions and dysregulations during cardiometabolic disease. Npj Metab Health Dis. 2024;2:34. https:\/\/doi.org\/10.1038\/s44324-024-00036-z.","journal-title":"Npj Metab Health Dis"},{"key":"336_CR91","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"336_CR92","unstructured":"(2012) Epidemiology of Cardiovascular Disease. In: Goldman\u2019s Cecil Medicine. W.B. Saunders, pp 256\u201360."},{"key":"336_CR93","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1530\/EJE-20-0370","volume":"183","author":"G Gava","year":"2020","unstructured":"Gava G, Mancini I, Alvisi S, et al. A comparison of 5-year administration of cyproterone acetate or leuprolide acetate in combination with estradiol in transwomen. Eur J Endocrinol. 2020;183:561\u20139. https:\/\/doi.org\/10.1530\/EJE-20-0370.","journal-title":"Eur J Endocrinol"},{"key":"336_CR94","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1038\/s41366-021-00935-x","volume":"45","author":"M Kyinn","year":"2021","unstructured":"Kyinn M, Banks K, Leemaqz SY, et al. Weight gain and obesity rates in transgender and gender-diverse adults before and during hormone therapy. Int J Obes. 2021;45:2562\u20139. https:\/\/doi.org\/10.1038\/s41366-021-00935-x.","journal-title":"Int J Obes"},{"key":"336_CR95","doi-asserted-by":"publisher","unstructured":"Deischinger C, Slukova D, Just I et al. Effects of gender-affirming hormone therapy on cardiovascular risk factors focusing on glucose metabolism in an Austrian transgender cohort. Int J Transgender Health 24:499\u2013509. https:\/\/doi.org\/10.1080\/26895269.2022.2123425","DOI":"10.1080\/26895269.2022.2123425"},{"key":"336_CR96","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.amepre.2024.10.001","volume":"68","author":"TC Poteat","year":"2025","unstructured":"Poteat TC, Ehrig M, Ahmadi H, et al. Hormones, Stress, and Heart Disease in Transgender Women with HIV in LITE Plus. Am J Prev Med. 2025;68:245\u201356. https:\/\/doi.org\/10.1016\/j.amepre.2024.10.001.","journal-title":"Am J Prev Med"}],"container-title":["Cardiovascular Diabetology \u2013 Endocrinology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40842-026-00336-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40842-026-00336-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:14:15Z","timestamp":1791238455000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40842-026-00336-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["336"],"URL":"https:\/\/doi.org\/10.1186\/s40842-026-00336-x","relation":{"references":[{"id-type":"doi","id":"10.1016\/j.focus.2023.100096","asserted-by":"subject"}]},"ISSN":["3059-4057"],"issn-type":[{"value":"3059-4057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"64"}}